TY - JOUR T1 - Has the age distribution of hospitalized Covid-19 patients changed in Brazil? JF - medRxiv DO - 10.1101/2021.03.30.21254650 SP - 2021.03.30.21254650 AU - Carla Lourenço Tavares de Andrade AU - Sheyla Maria Lemos Lima AU - Monica Martins AU - Claudia Cristina de Aguiar Pereira AU - Margareth Crisóstomo Portela Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254650.abstract N2 - The aim of this study was to compare the age profile of hospitalized Covid-19 patients during the first year of the pandemic, as well as hospital mortality and use of ICUs, by age group, in large geographic regions of Brazil. We used data from the Influenza Epidemiological Surveillance Information System for patients who presented the first symptoms of the disease between the epidemiological weeks 8 of 2020 and 7 of 2021, which were divided into three periods.779,257 records of patients hospitalized by Covid-19 were obtained. Of this total, 720,363 (92.4%) referred to discharged hospitalizations, considered in the analysis of ICU use and death. Among 244,611 hospitalizations (34.0%) with indication for use of ICU, 190,833 allowed the calculation of the time in ICU. There was variation in the age profile of hospitalized patients between the three periods, but there was no evidence in favor of the hypothesis of an increase, in the last period, in the participation of adults between 18 and 50 years old in hospitalizations by Covid-19. A differentiated increase in the mortality of young adults in the North suggests the possibility of greater severity of the P1 variant in this population. The results also show that the participation of young adults in hospitalizations and hospital deaths was never negligible and is related to hospital mortality rates close to or above 10%.The Covid-19 “youthening” phenomenon in Brazil is based on the country’s own sociodemographic and economic characteristics and may have been strengthened by the increasing circulation of viral variants. It is important to continue monitoring its progression and effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTh work had no financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work is based on public available data. It was not required to be submitted to a Ethical Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yeshave followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript is based on data publicly available. https://opendatasus.saude.gov.br ER -